TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04783168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit to monitor step count

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit to monitor step count

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04257097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RPM - Osteogenics Lubbock Texas USA
Description: 25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
Study: NCT05417529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy intervention
Description: Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
Study: NCT04257097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yxoss CBR - Reoss Filderstadt Germany
Description: 25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
Study: NCT03541876

Intervention type: OTHER
Intervention: Collection of data
Description: The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control.
Study: NCT01289782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
Study: NCT04525027

Intervention type: DIAGNOSTIC_TEST
Intervention: intra-abdominal pressure in severe acute pancreatitis
Description: daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome

Intervention type: DIAGNOSTIC_TEST
Intervention: intra-abdominal pressure in severe acute pancreatitis
Description: daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
Study: NCT03425344

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic
Description: No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
Study: NCT01949805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-P-IFN-alpha-2b (AOP2014)
Description: Pegylated interferon alpha 2b given Q2W as SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroyurea capsules taken daily po
Study: NCT00587730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GE Attenuation Corrected Hawkeye Camera
Description: GE Hawkeye AC system and 360˚ camera orbit
Study: NCT03262051

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP phenotyping
Description: Phenotyping using a simplified version of the Geneva cocktail

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP phenotyping
Description: Phenotyping using a simplified version of the Geneva cocktail

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP phenotyping
Description: Phenotyping using a simplified version of the Geneva cocktail
Study: NCT00576654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01289782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study: NCT02789319

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems
Study: NCT01154049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sm14 antigen plus adjuvant GLA
Description: Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
Study: NCT00492622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole
Description: Immediate-release omeprazole 40 mg qam for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole
Description: Immediate-release omeprazole 40 mg qam for 7 days
Study: NCT01087619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroid surgery
Description: Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
Study: NCT03600103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tech2Check
Description: The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
Study: NCT04191733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KINCISE(TM) Surgical Automated System
Description: Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KINCISE(TM) Surgical Automated System
Description: Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
Study: NCT02842281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructan
Description: Short-chain oligosaccharide primarily composed of fructose polymers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Polysaccharide produced from starch
Study: NCT03159442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
Study: NCT00492622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed-release omeprazole
Description: Delayed-release omeprazole 40 mg qam for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed-release omeprazole
Description: Delayed-release omeprazole 40 mg qam for 7 days
Study: NCT02805699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baofeikang Granule
Description: To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
Study: NCT00999752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
Study: NCT00576654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT02939573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Randomized to colchicine 0.6 mg x 2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Randomized to colchicine 0.6 mg x 2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: Randomized to dapsone 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: Randomized to dapsone 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Randomized to azathioprine 2 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Randomized to azathioprine 2 mg/kg/day
Study: NCT00615823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
Study: NCT00749658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
Study: NCT02179788

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~* Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~* Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~* Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)
Study: NCT02179788

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.
Study: NCT04413799

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, ketamine intravenous infusion
Description: Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to lidocaine/ketamine group, the anesthesiologist led Acute Pain Service (APS) will prescribe lidocaine/ ketamine infusion, which will be monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block with ropivicaine
Description: Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to PVB, the anesthesiologist led Acute Pain Service (APS) will place a paravertebral block catheter. Ropivacaine infusion will be started, monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups
Study: NCT03391505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small-sided soccer game
Description: The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking soccer game
Description: The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rest group watching soccer
Description: The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
Study: NCT03698357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive video balance-based exercise
Description: Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
Study: NCT04468880

Intervention type: OTHER
Group type: OTHER
Intervention: Group (A1 → A2)
Description: Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out.
Study: NCT00999752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg/day
Study: NCT02795598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single injection supraclavicular nerve block
Description: The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double injection supraclavicular nerve block
Description: The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread.
Study: NCT02789319

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems
Study: NCT04468880

Intervention type: OTHER
Group type: OTHER
Intervention: Group (A2 → A1)
Description: Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out.